Use of Chimeric Antigen Receptor Modified T Cells With Extensive Leukemic Myocardial InvolvementBrian Han, Lillian Su, Raúl Montiel-Esparza et al.|JACC CardioOncology|2020Cited by 2
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategiesAlexandra Dreyzin, Nirali N. Shah, Dorota D. Klysz et al.|Cytotherapy|2025Cited by 1
CD22 CAR T-Cells Manufactured in Prodigy System and in Bag Culture Yield Equivalent Responses for B-ALLAlexandra Dreyzin, Nirali N. Shah, Anne Marijn Kramer et al.|Transplantation and Cellular Therapy|2024Cited by 0